MX2018007680A - Acidos nucleicos que codifican secuencias repetitivas de aminoacidos ricas en residuos de prolina y alanina que tienen secuencias nucleotidicas con baja repetitividad. - Google Patents
Acidos nucleicos que codifican secuencias repetitivas de aminoacidos ricas en residuos de prolina y alanina que tienen secuencias nucleotidicas con baja repetitividad.Info
- Publication number
- MX2018007680A MX2018007680A MX2018007680A MX2018007680A MX2018007680A MX 2018007680 A MX2018007680 A MX 2018007680A MX 2018007680 A MX2018007680 A MX 2018007680A MX 2018007680 A MX2018007680 A MX 2018007680A MX 2018007680 A MX2018007680 A MX 2018007680A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acid
- amino acid
- repetitive
- proline
- low
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/68—Stabilisation of the vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Analytical Chemistry (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se relaciona con una molécula de ácidos nucleicos que comprende una secuencia nucleotídica con baja repetitividad que codifica una secuencia repetitiva de aminoácidos rica en prolina/alanina. El polipéptido codificado comprende una secuencia repetitiva de aminoácidos que forma una espira aleatoria. La molécula de ácidos nucleicos que comprende las secuencias nucleotídicas con baja repetitividad puede comprender además, una secuencia nucleotídica que codifica una proteína biológica o farmacológicamente activa. Además, la presente invención proporciona medios y métodos de selección para identificar la molécula de ácidos nucleicos que comprende la secuencia nucleotídica con baja repetitividad. La presente invención también se relaciona con un método para preparar las moléculas de ácidos nucleicos. También se proporcionan en el presente documento métodos para preparar el polipéptido codificado o conjugados del fármaco con el polipéptido codificado utilizando las moléculas de ácidos nucleicos proporcionadas en el presente documento. El conjugado del fármaco puede comprender una proteína biológica o farmacológicamente activa o un fármaco de molécula pequeña. También se proporcionan en el presente documento vectores y hospederos que comprenden tales moléculas de ácidos nucleicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15202093 | 2015-12-22 | ||
PCT/EP2016/082407 WO2017109087A1 (en) | 2015-12-22 | 2016-12-22 | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018007680A true MX2018007680A (es) | 2018-11-14 |
Family
ID=55129435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018007680A MX2018007680A (es) | 2015-12-22 | 2016-12-22 | Acidos nucleicos que codifican secuencias repetitivas de aminoacidos ricas en residuos de prolina y alanina que tienen secuencias nucleotidicas con baja repetitividad. |
Country Status (19)
Country | Link |
---|---|
US (1) | US11401305B2 (es) |
EP (2) | EP3919623A1 (es) |
JP (1) | JP7065772B2 (es) |
KR (1) | KR102654180B1 (es) |
CN (1) | CN109153996B (es) |
AU (1) | AU2016378646B2 (es) |
BR (1) | BR112018012784A2 (es) |
CA (1) | CA3005115A1 (es) |
DK (1) | DK3394266T3 (es) |
EA (1) | EA201891127A1 (es) |
ES (1) | ES2877539T3 (es) |
HU (1) | HUE055267T2 (es) |
IL (1) | IL259352B (es) |
LT (1) | LT3394266T (es) |
MX (1) | MX2018007680A (es) |
PL (1) | PL3394266T3 (es) |
SG (1) | SG11201803958WA (es) |
SI (1) | SI3394266T1 (es) |
WO (1) | WO2017109087A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
US10174302B1 (en) | 2017-06-21 | 2019-01-08 | Xl-Protein Gmbh | Modified L-asparaginase |
CN111406071B (zh) * | 2017-11-16 | 2024-01-16 | 成都硕德药业有限公司 | Pas化的vegfr/pdgfr融合蛋白及其在治疗中的用途 |
EP3710483A4 (en) * | 2017-11-16 | 2021-10-20 | XL-protein GmbH | PASYLATED VEGFR / PDGFR FUSION PROTEINS AND THEIR USE IN THERAPY |
WO2019118921A1 (en) | 2017-12-14 | 2019-06-20 | Flodesign Sonics, Inc. | Acoustic transducer drive and controller |
US12016889B2 (en) | 2018-02-23 | 2024-06-25 | 9 Meters Biopharma, Inc. | Compositions and methods for treating or preventing intestinal paracellular permeability |
KR102209198B1 (ko) * | 2019-04-02 | 2021-02-02 | 주식회사 바이오앱 | 식물에서의 발현이 최적화된 재조합 이리신 유전자 및 이를 이용한 재조합 이리신 단백질의 생산 방법 |
CN110038120B (zh) * | 2019-04-02 | 2022-12-23 | 河南师范大学 | 豹蛙抗瘤酶融合蛋白作为治疗肿瘤药物的应用 |
US20200327961A1 (en) * | 2019-04-15 | 2020-10-15 | Bruker Daltonik Gmbh | Methods for determining isomeric amino acid residues of proteins and peptides |
WO2020227341A1 (en) * | 2019-05-06 | 2020-11-12 | 9 Meters Biopharma, Inc. | Compositions and methods for treating sjogren's syndrome |
IL303816A (en) | 2020-12-22 | 2023-08-01 | Xl Protein Gmbh | Antibodies specific for structurally disordered sequences |
CN113340864B (zh) * | 2021-06-07 | 2023-04-07 | 郑州轻工业大学 | 基于mef效应二次放大ins信号的适体传感器及其制备方法和应用 |
CN114470170B (zh) * | 2022-02-22 | 2023-09-19 | 广州新济药业科技有限公司 | 一种司美格鲁肽可溶性微针组合物及其制备方法 |
WO2024042236A1 (en) | 2022-08-26 | 2024-02-29 | Ethris Gmbh | Stable lipid or lipidoid nanoparticle suspensions |
GB202218084D0 (en) | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
WO2024124142A2 (en) * | 2022-12-08 | 2024-06-13 | Insmed Incorporated | Uricase conjugates and methods of use thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
WO1994029469A2 (en) | 1993-06-07 | 1994-12-22 | Vical Incorporated | Plasmids suitable for gene therapy |
CA2225460A1 (en) | 1995-06-23 | 1997-01-09 | Winston Campbell Patterson | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
US7378506B2 (en) | 1997-07-21 | 2008-05-27 | Ohio University | Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins |
US20060252120A1 (en) | 2003-05-09 | 2006-11-09 | Kieliszewski Marcia J | Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins |
MX2008015213A (es) | 2006-05-30 | 2008-12-09 | Dow Global Technologies Inc | Metodo de optimizacion de codon. |
PL2173890T3 (pl) | 2007-06-21 | 2011-07-29 | Univ Muenchen Tech | Białka czynne biologicznie o zwiększonej stabilności in vivo i (lub) in vitro |
PL2571510T3 (pl) | 2010-05-21 | 2019-03-29 | Xl-Protein Gmbh | Biosyntetyczne polipeptydy prolinowo/alaninowe o strukturze kłębka statystycznego i ich zastosowania |
ES2704237T3 (es) | 2014-03-05 | 2019-03-15 | Merz Pharma Gmbh & Co Kgaa | Nuevas neurotoxinas clostridiales recombinantes con un aumento de la duración del efecto |
WO2018234492A1 (en) | 2017-06-21 | 2018-12-27 | Xl-Protein Gmbh | L-ASPARAGINASE MODIFIED |
EP3418383A1 (en) | 2017-06-21 | 2018-12-26 | XL-protein GmbH | Modified l-asparaginase |
US20200282071A1 (en) | 2017-06-21 | 2020-09-10 | Xl-Protein Gmbh | Conjugates of protein drugs and p/a peptides |
US10174302B1 (en) | 2017-06-21 | 2019-01-08 | Xl-Protein Gmbh | Modified L-asparaginase |
EP3710483A4 (en) | 2017-11-16 | 2021-10-20 | XL-protein GmbH | PASYLATED VEGFR / PDGFR FUSION PROTEINS AND THEIR USE IN THERAPY |
-
2016
- 2016-12-22 CN CN201680072372.2A patent/CN109153996B/zh active Active
- 2016-12-22 BR BR112018012784A patent/BR112018012784A2/pt active Search and Examination
- 2016-12-22 EA EA201891127A patent/EA201891127A1/ru unknown
- 2016-12-22 PL PL16828736T patent/PL3394266T3/pl unknown
- 2016-12-22 EP EP21166789.4A patent/EP3919623A1/en not_active Withdrawn
- 2016-12-22 WO PCT/EP2016/082407 patent/WO2017109087A1/en active Application Filing
- 2016-12-22 MX MX2018007680A patent/MX2018007680A/es unknown
- 2016-12-22 ES ES16828736T patent/ES2877539T3/es active Active
- 2016-12-22 SI SI201631254T patent/SI3394266T1/sl unknown
- 2016-12-22 SG SG11201803958WA patent/SG11201803958WA/en unknown
- 2016-12-22 JP JP2018532638A patent/JP7065772B2/ja active Active
- 2016-12-22 CA CA3005115A patent/CA3005115A1/en active Pending
- 2016-12-22 DK DK16828736.5T patent/DK3394266T3/da active
- 2016-12-22 HU HUE16828736A patent/HUE055267T2/hu unknown
- 2016-12-22 KR KR1020187020867A patent/KR102654180B1/ko active IP Right Grant
- 2016-12-22 LT LTEP16828736.5T patent/LT3394266T/lt unknown
- 2016-12-22 US US16/064,951 patent/US11401305B2/en active Active
- 2016-12-22 AU AU2016378646A patent/AU2016378646B2/en active Active
- 2016-12-22 EP EP16828736.5A patent/EP3394266B1/en active Active
-
2018
- 2018-05-14 IL IL259352A patent/IL259352B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR102654180B1 (ko) | 2024-04-04 |
LT3394266T (lt) | 2021-08-25 |
HUE055267T2 (hu) | 2021-11-29 |
JP2019508020A (ja) | 2019-03-28 |
EA201891127A1 (ru) | 2019-01-31 |
US20190010192A1 (en) | 2019-01-10 |
BR112018012784A2 (pt) | 2019-02-05 |
ES2877539T3 (es) | 2021-11-17 |
CN109153996A (zh) | 2019-01-04 |
IL259352A (en) | 2018-07-31 |
AU2016378646A1 (en) | 2018-06-14 |
JP7065772B2 (ja) | 2022-05-12 |
KR20180088484A (ko) | 2018-08-03 |
IL259352B (en) | 2022-02-01 |
EP3394266A1 (en) | 2018-10-31 |
WO2017109087A1 (en) | 2017-06-29 |
EP3919623A1 (en) | 2021-12-08 |
US11401305B2 (en) | 2022-08-02 |
PL3394266T3 (pl) | 2021-12-13 |
EP3394266B1 (en) | 2021-04-14 |
SG11201803958WA (en) | 2018-07-30 |
SI3394266T1 (sl) | 2021-08-31 |
NZ742902A (en) | 2023-12-22 |
DK3394266T3 (da) | 2021-06-07 |
CA3005115A1 (en) | 2017-06-29 |
AU2016378646B2 (en) | 2023-03-09 |
CN109153996B (zh) | 2022-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018007680A (es) | Acidos nucleicos que codifican secuencias repetitivas de aminoacidos ricas en residuos de prolina y alanina que tienen secuencias nucleotidicas con baja repetitividad. | |
RU2017134456A (ru) | Рекомбинантные связывающие белки и их применение | |
NZ602522A (en) | Biosynthetic proline/alanine random coil polypeptides and their uses | |
CY1117351T1 (el) | Κυτταροδιαπερατοι αναστολεις πεπτιδιων της jnk-σηματοδοτικης πορειας μεταγωγης | |
EA201100070A1 (ru) | Туберкулезный белок rv2386c, композиции и их применения | |
WO2014202616A3 (en) | Rasamsonia gene and use thereof | |
MX2022001134A (es) | Proteinas quimericas de factor viii y usos de estas. | |
SA522433360B1 (ar) | L-أَسْباراجيناز مُعدل | |
PE20142451A1 (es) | Composiciones de conjugados de xten y metodos para realizar las mismas | |
WO2016094873A3 (en) | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods | |
UA110599C2 (uk) | Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку | |
WO2017025179A8 (en) | A transglutamine tag for efficient site-specific bioconjugation | |
EP3936141A3 (en) | Anti-senescence compounds and uses thereof | |
UA107180C2 (uk) | Туберкульозний білок rv1753c, композиція, що його містить, та застосування | |
ZA202101376B (en) | Tertiary amino lipidated cationic peptides for nucleic acid delivery | |
MX363443B (es) | Proteinas de tipo espiral enrollada modificadas que tienen propiedades mejoradas. | |
EP4269562A3 (en) | Antigen binding molecules and methods of use thereof | |
WO2016130628A8 (en) | Griffithsin mutants | |
IL261112A (en) | Conjugations of amino acid and peptide and conjugation process | |
WO2015107363A3 (en) | Mycobacterial antigen composition | |
PE20230343A1 (es) | Peptidos que estimulan respuestas inmunitarias antitumorales | |
PH12020551955A1 (en) | Anti-cd63 antibodies, conjugates, and uses thereof | |
WO2011135222A3 (fr) | Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles | |
MX2010005816A (es) | Epítopos de péptido de stat3. | |
GB2487299B (en) | Method of performing a site-specific chiral inversion in a tripeptide |